Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Honghong Zhou

Showing results (41-50 of 94) with videos related to

Pageof 10
Sort By:
The Prostate|April 15, 2008
Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysisRebecca A Marks, Shaobo Zhang, Rodolfo Montironi, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 30, 2019
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosisSeth Walker, Patrick Flume, John McNamara, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 10, 2023
All-Trans Retinoic Acid Promotes a Tumor Suppressive OTUD6B-β-TrCP-SNAIL Axis in Esophageal Squamous Cell Carcinoma and Enhances ImmunotherapyLei Li, Rui Zhu, Honghong Zhou, et al.
The New England Journal of Medicine|August 11, 2021
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in AdolescentsKashif Ali, Gary Berman, Honghong Zhou, et al.
Eclinicalmedicine|August 2, 2024
Safety and durability of mRNA-1273-induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trialAmparo L Figueroa, Kashif Ali, Gary Berman, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2014
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancerJoe J Stephenson, John Nemunaitis, Anil A Joy, et al.
Annals of Internal Medicine|July 5, 2022
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical TrialDean Follmann, Holly E Janes, Olive D Buhule, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2022
Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE TrialsUma Siangphoe, Lindsey R Baden, Hana M El Sahly, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 11, 2023
Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trialNima S Hejazi, Xiaoying Shen, Lindsay N Carpp, et al.
Cell & Bioscience|November 27, 2025
Deciphering the epigenomic regulatory variations reveals function diversity in adipose lineage among different adipose depots of pigsDaoyuan Wang, Renzhuo Kuang, Mingyang Hu, et al.
Pageof 10

Showing results (41-50 of 94) with videos related to

Sort By:
Pageof 10
The Prostate|April 15, 2008
Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysisRebecca A Marks, Shaobo Zhang, Rodolfo Montironi, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 30, 2019
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosisSeth Walker, Patrick Flume, John McNamara, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 10, 2023
All-Trans Retinoic Acid Promotes a Tumor Suppressive OTUD6B-β-TrCP-SNAIL Axis in Esophageal Squamous Cell Carcinoma and Enhances ImmunotherapyLei Li, Rui Zhu, Honghong Zhou, et al.
The New England Journal of Medicine|August 11, 2021
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in AdolescentsKashif Ali, Gary Berman, Honghong Zhou, et al.
Eclinicalmedicine|August 2, 2024
Safety and durability of mRNA-1273-induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trialAmparo L Figueroa, Kashif Ali, Gary Berman, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2014
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancerJoe J Stephenson, John Nemunaitis, Anil A Joy, et al.
Annals of Internal Medicine|July 5, 2022
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical TrialDean Follmann, Holly E Janes, Olive D Buhule, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2022
Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE TrialsUma Siangphoe, Lindsey R Baden, Hana M El Sahly, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 11, 2023
Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trialNima S Hejazi, Xiaoying Shen, Lindsay N Carpp, et al.
Cell & Bioscience|November 27, 2025
Deciphering the epigenomic regulatory variations reveals function diversity in adipose lineage among different adipose depots of pigsDaoyuan Wang, Renzhuo Kuang, Mingyang Hu, et al.
Pageof 10